NeoGenomics Announces Opening of Laboratory in Singapore

NeoGenomics, Inc., a provider of cancer-focused genetics testing services, and Pharmaceutical Product Development, LLC, a global contract research organization, have announced the grand opening of a NeoGenomics oncology-focused clinical trials testing lab in the same building as the PPD Laboratories central lab in Singapore. 

NeoGenomics’ Pharmaceutical Services Division has established a track record of rapid growth and is building a global network for clinical trials. After opening and operating a College of American Pathologists (CAP) accredited facility in Rolle, Switzerland since 2017 to service European clinical trials, NeoGenomics prioritized additional expansion into Singapore to service the Asia-Pacific region and allow for global clinical trial placement. NeoGenomics Chairman and Chief Executive Officer, Doug VanOort noted, “Our customers in the Pharmaceutical Services Division are truly global customers who want the ability to place studies wherever they can find the enrollees. They are looking to partner with laboratories that provide great service and high quality, consistent testing across the globe. We’re very excited about our Singapore laboratory and the potential growth opportunity we see within the Asia-Pacific region. This is another milestone in our plan to be a premier global provider of services to the pharmaceutical industry.” 

NeoGenomics and PPD formed an alliance in 2018 to provide premier laboratory testing solutions for oncology clinical trials and biomarker research and development. Through the collaboration, NeoGenomics provides a wide range of lab testing services to support PPD Laboratories’ oncology clinical trial activities in North America, Europe and Asia-Pacific. This expansion in Singapore is part of the companies’ established plan to invest in PPD’s existing labs service offerings in China and Singapore. It also augments PPD Laboratories’ offerings of specialized oncology and pathology biomarker testing for biopharmaceutical customers and advances the companies’ initiative to provide an integrated, global solution for complex development programs. 

“This expansion of our collaboration with NeoGenomics in Singapore is a critical step in enhancing our pathology and molecular capabilities in the Asia-Pacific region, one of the fastest-growing areas of the world for clinical trials,” said Christopher Fikry, M.D., executive vice president of PPD Laboratories. “We look forward to further strengthening our alliance with NeoGenomics and jointly supporting global and regional oncology trials.” 

Fully integrated with PPD’s CRO capabilities, PPD Laboratories offers bioanalytical, biomarkers, central lab, GMP and vaccine sciences. 

Douglas VanOort added, “Our mutual clients are excited about NeoGenomics having the capability to handle testing for their study enrollees across the globe. We are thrilled to expand our collaboration with PPD by providing clients with even greater access to our scientific and clinical professionals, as well as best-in-class oncology testing.”